1)国立感染症研究所感染症疫学センター:麻疹2016年.IASR 38:1-3, 2017 http://www0.nih.go.jp/niid/idsc/iasr/38/445.pdf
2)国立感染症研究所感染症疫学センター:2013年度麻疹予防接種状況および抗体保有状況—2013年度感染症流行予測調査(中間報告).IASR 35:109-111, 2014 http://www0.nih.go.jp/niid/idsc/iasr/35/410j.pdf
3)国立感染症研究所感染症疫学センター:感染症発生動向調査における,麻疹の実験室診断例(取り下げ例を含む)の推移,2011〜2015年.IASR 37:69-70, 2016 http://www0.nih.go.jp/niid/idsc/iasr/37/434.pdf
4)Watanabe A, et al:Exposure to H1 genotype measles virus at an international airport in Japan on 31 July 2016 results in a measles outbreak. WPSAR 81-3, 2017. http://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/517/741
5)国立感染症研究所感染症疫学センター:関西国際空港の利用日および/またはウイルス遺伝子型が共通する麻しん報告例.http://www.niid.go.jp/niid/ja/hassei/6865-measles-kankuu-20161102.html
6)国立感染症研究所感染症疫学センター:関西国際空港内事業所での麻疹集団感染事例について.IASR 38:48-49, 2017 http://www.nih.go.jp/niid/ja/allarticles/surveillance/2405-iasr/related-articles/related-articles-445/7131-445r01.html
7)Suga S, et al:Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children:Effects of the seven-valent pneumococcal conjugate vaccine. Vaccine 33:6054-6560, 2015
8)Fukusumi M, et al:Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015:Disease characteristics and serotype distribution. BMC Infect Dis 17:2, 2017
9)Fukuyama H, et al:Validation of sputum gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia:a prospective observational study. BMC Infect Dis 14:534, 2014
10)Shindo Y, et al:Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 188:985-995, 2013
11)Morimoto K, et al:The burden and etiology of community-onset pneumonia in the aging Japanese population:a multicenter prospective study. PLoS One 10:e0122247, 2015
12)Isozumi R, et al:Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol. 45:1440-1446, 2007
serotypes in adult Japanese patients with pneumococcal pneumonia from 2011 to 2015. J Infect Chemother 23:301-306, 2017
14)Suzuki M, et al:Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older:a multicentre, prospective, test-negative design study. Lancet Infect Dis 17:313-321, 2017 https://doi.org/10.1016/S1473-3099(17)30049-X